Platelet-fibrin clot strength and platelet reactivity predicting cardiovascular events after percutaneous coronary interventions
Authors' conclusion
In PCI patients, PFCS and platelet reactivity demonstrated important relationships in predicting clinical prognosis.
Study context
- Population
- Percutaneous coronary intervention (PCI)-treated patients, South Korean registry, January 2010 to November 2018
- Participants
- 2,512 patients
- Exposure
- Platelet reactivity and platelet-fibrin clot strength phenotypes
- Outcome
- MACE:
- All-cause death
- MI
- Stroke
- Follow-up
- Up to 4 years
Main finding
As reported in the abstract
MACE
Adjusted hazard ratio (95% CI)P value
HPR-PFCSHighvs NPR-PFCSNormal
1.89(1.23–2.91)
P = 0.004HPR-PFCSHighvs HPR-PFCSNormal
1.60(1.12–2.27)
P = 0.009- Additive effect of high platelet reactivity (HPR) and PFCSHigh on clinical outcomes (log-rank)
- P < 0.001
Observational data: associations, not effects.
Further findings
All-cause death
- Similar results as for major adverse cardiovascular event (MACE)
Safety
| Outcome | Adjusted HR (95% CI) | P value | |
|---|---|---|---|
| Major bleedingNPR-PFCSNormalvs HPR-PFCSNormal | 3.12 (1.30–7.69) | P = 0.010 | |
| 0.10.31310Adjusted hazard ratio (log scale) |
Original publication
Platelet-fibrin clot strength and platelet reactivity predicting cardiovascular events after percutaneous coronary interventions. Eur Heart J. Published 28 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →